David F.  Novack net worth and biography

David Novack Biography and Net Worth

Mr. Novack joined Dynavax in 2013, and currently serves as President and Chief Operating Officer. Previously, Mr. Novack served as Senior Vice President of Operations where he led the company’s technical operations, supply chain, and quality teams through FDA approval, launch and commercialization of HEPLISAV-B. Mr. Novack has more than 30 years of relevant industry experience, with more than 20 years of direct vaccine industry experience. Prior to Dynavax, Mr. Novack was at Novartis where he served in various roles, including Global Head of Technical Operations and Supply Chain for Diagnostics, and Global Head of Manufacturing Strategy for Vaccines. Prior to Novartis, Mr. Novack held management positions at MedImmune and Lederle Laboratories (now Pfizer). Mr. Novack received a B.S. in Biology from the State University of New York at Albany, and an M.B.A. from Columbia University.

What is David F. Novack's net worth?

The estimated net worth of David F. Novack is at least $36,618.63 as of January 2nd, 2024. Mr. Novack owns 3,187 shares of Dynavax Technologies stock worth more than $36,619 as of April 16th. This net worth evaluation does not reflect any other assets that Mr. Novack may own. Additionally, Mr. Novack receives an annual salary of $925,600.00 as COO at Dynavax Technologies. Learn More about David F. Novack's net worth.

How old is David F. Novack?

Mr. Novack is currently 62 years old. There are 4 older executives and no younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies is Dr. Robert Janssen, Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs, who is 70 years old. Learn More on David F. Novack's age.

What is David F. Novack's salary?

As the COO of Dynavax Technologies Co., Mr. Novack earns $925,600.00 per year. The highest earning executive at Dynavax Technologies is Mr. Ryan Spencer, CEO & Director, who commands a salary of $1,250,000.00 per year. Learn More on David F. Novack's salary.

How do I contact David F. Novack?

The corporate mailing address for Mr. Novack and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]. Learn More on David F. Novack's contact information.

Has David F. Novack been buying or selling shares of Dynavax Technologies?

David F. Novack has not been actively trading shares of Dynavax Technologies over the course of the past ninety days. Most recently, David F. Novack sold 9,000 shares of the business's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.45, for a transaction totalling $130,050.00. Following the completion of the sale, the chief operating officer now directly owns 3,187 shares of the company's stock, valued at $46,052.15. Learn More on David F. Novack's trading history.

Who are Dynavax Technologies' active insiders?

Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.

Are insiders buying or selling shares of Dynavax Technologies?

In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 2,260,829 shares worth more than $31,645,244.29. The most recent insider tranaction occured on March, 1st when CAO Justin Burgess sold 20,526 shares worth more than $262,322.28. Insiders at Dynavax Technologies own 9.3% of the company. Learn More about insider trades at Dynavax Technologies.

Information on this page was last updated on 3/1/2024.

David F. Novack Insider Trading History at Dynavax Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2024Sell9,000$14.45$130,050.003,187View SEC Filing Icon  
12/1/2023Sell20,000$13.56$271,200.003,187View SEC Filing Icon  
11/3/2023Sell20,000$15.00$300,000.003,187View SEC Filing Icon  
11/1/2023Sell20,000$14.12$282,400.003,187View SEC Filing Icon  
10/2/2023Sell40,000$14.88$595,200.003,187View SEC Filing Icon  
9/1/2023Sell20,000$14.48$289,600.003,187View SEC Filing Icon  
8/8/2023Sell40,000$14.87$594,800.003,187View SEC Filing Icon  
5/4/2023Sell17,515$10.90$190,913.503,187View SEC Filing Icon  
11/8/2022Sell52,204$12.47$650,983.882,066View SEC Filing Icon  
8/9/2022Sell26,250$16.92$444,150.0053,213View SEC Filing Icon  
3/3/2022Sell41,862$10.57$442,481.34View SEC Filing Icon  
11/1/2021Sell20,000$20.12$402,400.00View SEC Filing Icon  
10/7/2021Sell3,000$18.00$54,000.00View SEC Filing Icon  
10/1/2021Sell17,000$18.23$309,910.00View SEC Filing Icon  
8/24/2021Sell10,000$14.00$140,000.00View SEC Filing Icon  
8/11/2021Sell10,000$12.00$120,000.00107,399View SEC Filing Icon  
4/1/2021Sell20,000$9.92$198,400.00137,399View SEC Filing Icon  
3/15/2018Sell16,109$16.30$262,576.70View SEC Filing Icon  
3/13/2018Sell34,214$16.52$565,215.2821,613View SEC Filing Icon  
3/9/2018Sell2,121$17.97$38,114.3777,192View SEC Filing Icon  
See Full Table

David F. Novack Buying and Selling Activity at Dynavax Technologies

This chart shows David F Novack's buying and selling at Dynavax Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dynavax Technologies Company Overview

Dynavax Technologies logo
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $11.49
Low: $11.47
High: $11.62

50 Day Range

MA: $12.44
Low: $11.69
High: $13.14

2 Week Range

Now: $11.49
Low: $10.06
High: $15.15


2,015,546 shs

Average Volume

1,936,658 shs

Market Capitalization

$1.50 billion

P/E Ratio


Dividend Yield